Deflazacort in Duchenne dystrophy

Study of long-term effect

C. Angelini, E. Pegoraro, E. Turella, M. T. Intino, A. Pini, C. Costa

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P <0.01), in rising from a chair, Gower's maneuver, and walking (P <0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P <0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P <0.02), and grade and time of Gower's maneuver (P <0.05) were found. The mean time for loss of ambulation for the treated group after we started the trial was 20.5 ± 11 months; for the placebo group it was 33.2 ± 9 months (placebo vs. deflazacort group, P <0.05). Our treated patients lost their ambulation at a median age of 11.8 years vs. 10.5 years in the placebo group. Side effects were mild, consisting of moderate weight gain and slight behavioral changes.

Original languageEnglish
Pages (from-to)386-391
Number of pages6
JournalMuscle and Nerve
Volume17
Issue number4
Publication statusPublished - 1994

Fingerprint

Walking
Placebos
Duchenne Muscular Dystrophy
Weight Gain
deflazacort
Therapeutics

Keywords

  • Duchenne dystrophy
  • steroid
  • trial

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Angelini, C., Pegoraro, E., Turella, E., Intino, M. T., Pini, A., & Costa, C. (1994). Deflazacort in Duchenne dystrophy: Study of long-term effect. Muscle and Nerve, 17(4), 386-391.

Deflazacort in Duchenne dystrophy : Study of long-term effect. / Angelini, C.; Pegoraro, E.; Turella, E.; Intino, M. T.; Pini, A.; Costa, C.

In: Muscle and Nerve, Vol. 17, No. 4, 1994, p. 386-391.

Research output: Contribution to journalArticle

Angelini, C, Pegoraro, E, Turella, E, Intino, MT, Pini, A & Costa, C 1994, 'Deflazacort in Duchenne dystrophy: Study of long-term effect', Muscle and Nerve, vol. 17, no. 4, pp. 386-391.
Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: Study of long-term effect. Muscle and Nerve. 1994;17(4):386-391.
Angelini, C. ; Pegoraro, E. ; Turella, E. ; Intino, M. T. ; Pini, A. ; Costa, C. / Deflazacort in Duchenne dystrophy : Study of long-term effect. In: Muscle and Nerve. 1994 ; Vol. 17, No. 4. pp. 386-391.
@article{a795a57b451d4491ae7658584f297318,
title = "Deflazacort in Duchenne dystrophy: Study of long-term effect",
abstract = "A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P <0.01), in rising from a chair, Gower's maneuver, and walking (P <0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P <0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P <0.02), and grade and time of Gower's maneuver (P <0.05) were found. The mean time for loss of ambulation for the treated group after we started the trial was 20.5 ± 11 months; for the placebo group it was 33.2 ± 9 months (placebo vs. deflazacort group, P <0.05). Our treated patients lost their ambulation at a median age of 11.8 years vs. 10.5 years in the placebo group. Side effects were mild, consisting of moderate weight gain and slight behavioral changes.",
keywords = "Duchenne dystrophy, steroid, trial",
author = "C. Angelini and E. Pegoraro and E. Turella and Intino, {M. T.} and A. Pini and C. Costa",
year = "1994",
language = "English",
volume = "17",
pages = "386--391",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Deflazacort in Duchenne dystrophy

T2 - Study of long-term effect

AU - Angelini, C.

AU - Pegoraro, E.

AU - Turella, E.

AU - Intino, M. T.

AU - Pini, A.

AU - Costa, C.

PY - 1994

Y1 - 1994

N2 - A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P <0.01), in rising from a chair, Gower's maneuver, and walking (P <0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P <0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P <0.02), and grade and time of Gower's maneuver (P <0.05) were found. The mean time for loss of ambulation for the treated group after we started the trial was 20.5 ± 11 months; for the placebo group it was 33.2 ± 9 months (placebo vs. deflazacort group, P <0.05). Our treated patients lost their ambulation at a median age of 11.8 years vs. 10.5 years in the placebo group. Side effects were mild, consisting of moderate weight gain and slight behavioral changes.

AB - A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P <0.01), in rising from a chair, Gower's maneuver, and walking (P <0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P <0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P <0.02), and grade and time of Gower's maneuver (P <0.05) were found. The mean time for loss of ambulation for the treated group after we started the trial was 20.5 ± 11 months; for the placebo group it was 33.2 ± 9 months (placebo vs. deflazacort group, P <0.05). Our treated patients lost their ambulation at a median age of 11.8 years vs. 10.5 years in the placebo group. Side effects were mild, consisting of moderate weight gain and slight behavioral changes.

KW - Duchenne dystrophy

KW - steroid

KW - trial

UR - http://www.scopus.com/inward/record.url?scp=0028280495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028280495&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 386

EP - 391

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -